Melatonin for primary insomnia?

Drug and Therapeutics Bulletin

Volumn 47, Issue 7, 2009, Pages 74-77

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN; PLACEBO; TEMAZEPAM; ZOLPIDEM; ZOPICLONE; CENTRAL DEPRESSANT AGENT;

ABDOMINAL PAIN; ABNORMAL DREAMING; ASTHENIA; BACKACHE; CIRCADIAN RHYTHM; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DRUG APPROVAL; DRUG COST; DRUG INDICATION; DRUG MARKETING; HEADACHE; HORMONAL THERAPY; HUMAN; HYPERACTIVITY; HYPERBILIRUBINEMIA; HYPERHIDROSIS; INSOMNIA; IRRITABILITY; MIGRAINE; NERVOUSNESS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHARYNGITIS; REM SLEEP; RESTLESSNESS; SHORT SURVEY; SIDE EFFECT; SOMNOLENCE; UNITED KINGDOM; WEAKNESS; WEIGHT GAIN; XEROSTOMIA; DRUG CONTRAINDICATION; DRUG EFFECT; ECONOMICS; MARKETING; RANDOMIZED CONTROLLED TRIAL; REVIEW;

CENTRAL NERVOUS SYSTEM DEPRESSANTS; CIRCADIAN RHYTHM; DRUG APPROVAL; DRUG COSTS; HUMANS; MARKETING; MELATONIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 70349573911     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2009.06.0024     Document Type: Short Survey

References (23)

1. European Medicines Agency, 2007. Assessment report for Circadin [online]. Available: http://www.emea.europa.eu/humandocs/PDFs/EPAR/circadin/H- 695-en6.pdf [Accessed 19 June 2009].
2. Buscemi N et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ, doi: 10.1136/bmj.38731.532766.F6 (published10 February 2006).
3. Buscemi N et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 2005; 20: 1151-8.
4. MacMahon K M et al. A systematic review of the effectiveness of oral melatonin for adults (18 to 65 years) with delayed sleep phase syndrome and adults (18 to 65 years) with primary insomnia. Curr Psychiatry Rev 2005; 1: 103-13.
5. Phillips L, Appleton RE. Systematic review of melatonin treatment in children with neurodevelopmental disabilities and sleep impairment. Dev Med Child Neurol 2004; 46: 771-5.
6. Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD001520. DOI: 10.1002/14651858.CD001520. [Last assessed as up-to-date: 11 February 2008].
7. Morphy H et al. Epidemiology of insomnia: a longitudinal study in a UK population. Sleep 2007; 30: 274-80.
8. What's wrong with prescribing hypnotics? DTB 2004; 42: 89-93.
9. National Institute for Clinical Excellence, 2004. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia. Technology appraisal guidance 77 [online]. Available: http://www.nice.org. uk/nicemedia/pdf/TA077fullguidance.pdf [Accessed.19 June 2009].
10. Joint Formulary Committee. British National Formulary. Edition 57. BMJ Group and RPS Publishing, March 2009.
11. Glass J et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ, doi:10.1136/bmj.38623.768588.47 (published 11 November 2005).
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington DC: American Psychiatric Association, 2000.
13. World Health Organization, 2006. International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Version for 2007 [online]. Available: http://www.who.int/classifications/apps/icd/ icd10online/navi.htm [Accessed 19 June 2009].
14. American Academy of Sleep Medicine. The International Classification of Sleep Disorders. 2nd ed: Diagnostic and coding manual. Westchester, Illinois: American Academy of Sleep Medicine, 2005.
15. Atalay H. Insomnia: recent developments in definition and treatment. Primary Care and Community Psychiatry. 2006; 11: 81-91.
16. Melatonin for jet lag? DTB 1998; 36: 15-6.
17. Witt-Enderby PA et al. Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci 2003; 72: 2183-98.
18. Circadin 2mg prolonged-release tablets. Summary of product characteristics, EU. Lundbeck Limited, 29/07/2008.
19. Lemoine P et al. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 2007; 16: 372-80.
20. Wade AG et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 patients: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 2007; 23: 2597-605.
21. The NHS Information Centre. Prescription Cost Analysis: England 2008 [online]. Available: http://www.ic.nhs.uk/webfiles/publications/ PCA%202008/PCA%202008v2.pdf [Accessed 19 June 2009].
22. Medicines and Healthcare products Regulatory Agency, 2008. Drug procurement advice. Restrictions on the import of unlicensed Melatonin products following the grant of a marketing authorisation for Circadin® 2mg tablets [online]. Available: http://www.mhra.gov.uk/NewsCentre/CON023251 [Accessed 19 June 2009].
23. Matthews G. Imported unlicensed medicines: requirements and current examples. Pharm J 2008; 281: 705-7.